Astellas Said Among Early Bidders To Acquire Optimer
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma, along with AstraZeneca and Cubist, are said to be among potential acquirers of Optimer Pharmaceuticals, a U.S.-based innovator of antibiotics considering a sale.